Karen Silence

Antithrombotic drug candidate ALX-0081 shows superior preclinical efficacy and safety compared with currently marketed antiplatelet drugs

Hans Ulrichts, Karen Silence, Anne Schoolmeester et al. · Blood · 2011 · 178 citations · Full text

A novel nanobody that detects the gain-of-function phenotype of von Willebrand factor in ADAMTS13 deficiency and von Willebrand disease type 2B

Janine J. J. Hulstein, Philip G. de Groot, Karen Silence et al. · Blood · 2005 · 147 citations · Full text

Acute activation of the endothelium results in increased levels of active von Willebrand factor in hemolysis, elevated liver enzymes and low platelets (HELLP) syndrome

Janine J. J. Hulstein, Pieter J. van Runnard Heimel, Arie Franx et al. · Journal of Thrombosis and Haemostasis · 2006 · 128 citations · Full text

Pathology, Inflammation, Thrombosis +16

ARGX-110, a highly potent antibody targeting CD70, eliminates tumors via both enhanced ADCC and immune checkpoint blockade

Karen Silence, Torsten Dreier, Mahan Moshir et al. · mAbs · 2013 · 100 citations · Full text

Immunology, Immunologic Mechanism, Immune Checkpoint Blockade +18

<scp>CD</scp>70 and <scp>PD</scp>‐L1 in anaplastic thyroid cancer – promising targets for immunotherapy

Karen Zwaenepoel, Julie Jacobs, Astrid De Meulenaere et al. · Histopathology · 2017 · 66 citations